Celltrion Healthcare Co., Ltd. operates a biopharmaceutical company in South Korea and internationally. Its biosimilar products include Remsima, Yuflyma, and Remsima SC, which are used for rheumatoid arthritis and inflammatory bowel diseases; Truxima that is used for non-hodgkin’s lymphoma, chronic lymphocytic leukemia, etc.; Herzuma, which is used for metastatic breast and metastatic gastric cancer; and Vegzelma for metastatic colorectal and non-small cell lung cancer. The company also provides novel therapeutics, such as Zymfentra that is used to treat inflammatory bowel disease; and Regkirona for the treatment of COVID-19. In addition, it offers small molecules products for tuberculosis, rare epilepsy, HIV/AIDS, and COVID-19, as well as test kits for COVID-19. The company was formerly known as Nexol, Inc. and changed its name to Celltrion Healthcare Co., Ltd. in March 2009. Celltrion Healthcare Co., Ltd. was founded in 1999 and is headquartered in Incheon, South Korea. Celltrion Healthcare Co., Ltd. is a subsidiary of Celltrion, Inc.